在优先人群中缺乏有关肛门癌的信息是阻碍预防服务的推广和利用的主要障碍。需要一个经过验证的肛门癌知识测量工具，以指导患者教育和共同的临床决策，用于肛门癌预防。本研究旨在验证“患者肛门癌知识量表”（PACKS）在美国生活的黑人和西班牙裔同性恋、双性恋和其他男性（GBM）以及年轻的性别扩展年轻成人（年龄在18-30岁之间）的样本（N=188）中的效度。假设肛门癌知识是一个由三个因子构成的量表，分别代表(1)风险和初级预防（9个项目），(2)症状（5个项目）和(3)筛查（3个项目）。进行了验证性因子分析、内部一致性和准则效度的评估。三因子模型表现出适当的拟合程度（RMSEA=0.02; CFI=0.99）。所有项目都与各自的因子有相关加载（p<0.01）。量表得分显示肛门癌知识偏低到中等水平，可接受的信度：因子1（M=3.5; SD=2.3; 范围：0-9; α=.71），因子2（M=2.9; SD=1.9; 范围：0-5; α=.85），和因子3（M=2.0; SD=1.2;范围：0-3; α=.79）。接种HPV疫苗的历史（51.3%）与因子1和2呈正相关。PACKS在肛门癌风险、预防、症状和筛查知识方面显示出良好的结构效度。黑人和西班牙裔GBM的有限肛门癌认知可能成为预防建议推广和利用的潜在障碍。©2023.作者（们）在美国癌症教育协会的独家许可下完成此翻译。

Lack of anal cancer information in priority populations is a major barrier to the uptake and utilization of prevention services. A validated measure of anal cancer knowledge is needed to inform patient education and shared clinical decision-making for anal cancer prevention. The purpose of this study was to validate the Patient Anal Cancer Knowledge Scale (PACKS) in a sample of GBM, namely Black and Hispanic gay, bisexual, and other men who have sex with men (GBM) and gender expansive young adults (aged 18-30 years) living in the USA (N=188). Anal cancer knowledge was hypothesized as a 3-factor scale representing (1) risk and primary prevention (9 items), (2) symptoms (5 items), and (3) screening (3 items). Confirmatory factor analysis, internal consistency, and criterion validity were assessed. The 3-factor model demonstrated adequate fit (RMSEA=0.02; CFI=0.99). All items loaded on their respective factors (p<0.01). Scale scores indicated low to moderate anal cancer knowledge and acceptable reliability: factor 1 (M=3.5; SD=2.3; range: 0-9; α=.71), factor 2 (M=2.9; SD=1.9; range: 0-5; α=.85), and factor 3 (M=2.0; SD=1.2; range: 0-3; α=.79). History of HPV vaccination (51.3%) was positively correlated with factors 1 and 2. The PACKS demonstrated good construct validity related to knowledge of anal cancer risk, prevention, symptoms, and screening. Limited anal cancer knowledge among Black and Hispanic GBM is a potential barrier to the uptake and utilization of prevention recommendations.© 2023. The Author(s) under exclusive licence to American Association for Cancer Education.